Market capitalization | $187.58m |
Enterprise Value | $102.76m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.26 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-99.67m |
Free Cash Flow (TTM) Free Cash Flow | $-91.36m |
Cash position | $131.61m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
10 Analysts have issued a Inozyme Pharma Inc forecast:
10 Analysts have issued a Inozyme Pharma Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.87 -0.87 |
33%
33%
|
|
EBITDA | -99 -99 |
39%
39%
|
EBIT (Operating Income) EBIT | -100 -100 |
38%
38%
|
Net Profit | -96 -96 |
42%
42%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
Head office | United States |
CEO | Doug Treco |
Employees | 59 |
Founded | 2015 |
Website | www.inozyme.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.